Literature DB >> 33905004

Associations Between Surrogates of Skeletal Muscle Mass and History of Bone Fracture in Patients with Chronic Kidney Disease: The Fukuoka Kidney disease Registry (FKR) Study.

Shunsuke Yamada1, Shigeru Tanaka1, Hokuto Arase1, Hiroto Hiyamuta1, Eriko Yoshizumi1, Masanori Tokumoto2, Toshiaki Nakano1, Kazuhiko Tsuruya3, Takanari Kitazono1.   

Abstract

Patients with chronic kidney disease (CKD) are at increased risks of both sarcopenia and fragility fractures. However, information on the association between skeletal muscle mass (SMM) and the risk of bone fractures in patients with CKD is lacking. We performed a cross-sectional analysis of 4146 patients with CKD using the baseline dataset of the Fukuoka Kidney disease Registry Study, as a multicenter, prospective cohort study of pre-dialysis CKD patients. The main measure was estimated SMM (eSMM) calculated using an equation validated by bioelectrical impedance analysis with two independent datasets of 100 and 81 CKD patients. The main outcome was historical bone fractures. The associations between sex-specific quartiles (Q1-Q4) of eSMM and fracture history were assessed by logistic regression analyses. The prevalence of a history of fractures increased and eSMM decreased with progressive CKD stages. Among the 4146 patients, 249 had prior bone fractures, including 111 patients in Q1 (lowest quartile), 65 in Q2, 46 in Q3, and 27 in Q4 (highest quartile). A multivariable-adjusted model revealed that patients in Q1 had a significantly higher odds ratio (95% confidence interval) for bone fracture history than those in Q4 (reference): Q1, 2.77 (1.32-5.80); Q2, 1.95 (1.05-3.65); and Q3, 1.57 (0.90-2.75) (P-value for trend < 0.001). Similar associations were obtained when other skeletal muscle surrogates were applied: serum creatinine to serum cystatin C and daily urinary creatinine excretion. These results suggest that a lower eSMM is associated with an increased prevalence of historical bone fractures in pre-dialysis CKD patients.

Entities:  

Keywords:  Bone fracture; Chronic kidney disease; Estimated skeletal muscle mass; Sarcopenia

Year:  2021        PMID: 33905004     DOI: 10.1007/s00223-021-00851-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  44 in total

1.  Effects of denosumab on fracture and bone mineral density by level of kidney function.

Authors:  Sophie A Jamal; Osten Ljunggren; Catherine Stehman-Breen; Steven Ron Cummings; Michael R McClung; Stefan Goemaere; Peter R Ebeling; Edward Franek; Yu-Ching Yang; Ogo I Egbuna; Steven Boonen; Paul D Miller
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

2.  The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease.

Authors:  Reid H Whitlock; William D Leslie; James Shaw; Claudio Rigatto; Laurel Thorlacius; Paul Komenda; David Collister; John A Kanis; Navdeep Tangri
Journal:  Kidney Int       Date:  2018-12-20       Impact factor: 10.612

3.  High rates of death and hospitalization follow bone fracture among hemodialysis patients.

Authors:  Minako Wakasugi; Junichiro J Kazama; Ichiei Narita
Journal:  Kidney Int       Date:  2014-09       Impact factor: 10.612

4.  Risk factors for hip fracture among patients with end-stage renal disease.

Authors:  C O Stehman-Breen; D J Sherrard; A M Alem; D L Gillen; S R Heckbert; C S Wong; A Ball; N S Weiss
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

5.  Incidence and risk factors for hip fractures in dialysis patients.

Authors:  M Maravic; A Ostertag; P U Torres; M Cohen-Solal
Journal:  Osteoporos Int       Date:  2013-07-09       Impact factor: 4.507

6.  Increased risk of hip fracture among patients with end-stage renal disease.

Authors:  A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

7.  Relationship between moderate to severe kidney disease and hip fracture in the United States.

Authors:  Thomas L Nickolas; Donald J McMahon; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

Review 8.  Fracture risk and treatment in chronic kidney disease.

Authors:  Kelsey Connelly; David Collister; Navdeep Tangri
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

Review 9.  Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Authors:  Lisa M Wilson; Casey M Rebholz; Ermias Jirru; Marisa Chi Liu; Allen Zhang; Jessica Gayleard; Yue Chu; Karen A Robinson
Journal:  Ann Intern Med       Date:  2017-04-11       Impact factor: 25.391

10.  High rates of death and hospitalization follow bone fracture among hemodialysis patients.

Authors:  Francesca Tentori; Keith McCullough; Ryan D Kilpatrick; Brian D Bradbury; Bruce M Robinson; Peter G Kerr; Ronald L Pisoni
Journal:  Kidney Int       Date:  2013-07-31       Impact factor: 10.612

View more
  2 in total

Review 1.  Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.

Authors:  Shunsuke Yamada; Kazuhiko Tsuruya; Takanari Kitazono; Toshiaki Nakano
Journal:  Clin Exp Nephrol       Date:  2022-03-30       Impact factor: 2.617

2.  "Sarcopenia and risk of osteoporosis, falls and bone fractures in patients with chronic kidney disease: A systematic review".

Authors:  Anahita Rashid; Sabina Chaudhary Hauge; Charlotte Suetta; Ditte Hansen
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.